Infleqtion enters the final stretch before its August 14 earnings with a lending market that remains near critically tight, a short position that has quintupled since mid-June, and a freshly assembled analyst consensus pointing to more than double the current share price.
The borrow picture tells the most urgent story. Availability — how much room is left in the lending pool — has been in near-freefall since the previous note on July 14 identified this structural shift. It briefly touched 0.69% on July 8, the tightest level of the past year, and while it has recovered marginally to 4.2% today, the lending pool remains essentially exhausted. For every 24 shares already borrowed, roughly one remains available to lend. That compares to availability above 500% as recently as June 19 — a collapse that took less than five weeks. Short interest has followed the same trajectory, climbing from roughly 4 million shares in mid-June to 25.3 million now, a 483% rise over the month. Cost to borrow has doubled since early June to 1.93%, running near its highest level of the recent build even after edging off Monday's intraday peak of 2.39%. The borrow market is not loosening.
Options positioning diverges from the lending signal. Call activity is running well ahead of puts — the put/call ratio is 0.32, below its 20-day average of 0.33 and more than half a standard deviation below that mean. It is also far below the 52-week high of 0.90. That skew toward calls implies options traders are positioned for upside rather than protection, a notable contrast to the level of short interest in the stock. The ORTEX short score of 66.6 has drifted higher across the past week but remains off its July 8-9 peak near 68.5, suggesting short pressure is elevated but not accelerating sharply.
The Street has been building its coverage universe around Infleqtion in recent weeks, and the direction has been uniformly positive. Canaccord Genuity initiated with a Buy and a $22 target on July 2. Wedbush had launched coverage the week prior with an Outperform and a $20 target. Citigroup initiated at Buy with a $20 target in April. Five analysts now carry Buy-equivalent ratings, with a consensus mean target of $20.60 — implying roughly 108% upside from Tuesday's close of $9.89. The company carries negative earnings yield and a deeply negative EV/EBITDA, reflecting pre-revenue deep-tech economics, so traditional valuation multiples offer little traction. The bull case rests on quantum computing commercialisation timelines; the bear case is the 27% share price decline over the past month alongside the structural short build.
Insider activity from late May and early June reinforces the cautious read. Maverick Capital, a hedge fund with board representation, sold more than 1.8 million shares across several transactions on May 29, collecting roughly $28 million in proceeds. CTO Pranav Gokhale sold 120,000 shares at $17.73 on June 4. A director sold 30,000 shares at $16.45 on May 28. Those transactions all cleared well above the current price, and no purchases have been recorded in the window. Net insider activity over the 90-day period registers as a sale of roughly 14.3 million shares in net terms — significant when set against a short interest position of 25 million shares.
Close peer IONQ fell nearly 10% on the week while QUBT declined around 1%, suggesting the quantum cohort broadly faced selling pressure even as INFQ managed a 9% single-session rebound on Tuesday after the prior week's losses. The August 14 earnings date is the next focal point — the May print saw the stock fall 6% on the day before recovering 11% over the subsequent five sessions, a pattern worth watching given how differently the lending market is positioned now versus then.
See the live data behind this article on ORTEX.
Open INFQ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
